Journal of Biological Chemistry · 2002 · 68 citations · 33 references
Veterinary MedicinePathobiologyPathologyInflammationMetastasisWound HealingChronic Wound PathophysiologyCytokine-mediated PathologyImmunopathology Of SkinInflammation-associated CarcinogenesisInflammatory MediatorsInflammatory SignalingCytokine-mediated Skin InflammationGelatinase ActivityMatrix Metalloproteinase ProcessingMatrix Metalloproteinase Regulation In HealingMatrix MetalloproteinasesNonhealing WoundsProinflammatory MediatorsProtease Activity In Wounds
The proteolytic activation of pro-matrix metalloproteinase (MMP)-9 by conversion of the 92-kDa precursor into an 82-kDa active form has been observed in chronic wounds, tumor metastasis, and many inflammation-associated diseases, yet the mechanistic pathway to control this process has not been identified. In this report, we show that the massive expression and activation of MMP-9 in skin tissue from patients with chronically unhealed wounds could be reconstituted in vitro with cultured normal human skin by stimulation with transforming growth factor-β and tumor necrosis factor (TNF)-α. We dissected the mechanistic pathway for TNF-α induced activation of pro-MMP-9 in human skin. We found that proteolytic activation of pro-MMP-9 was mediated by a tissue-associated chymotrypsin-like proteinase, designated here as pro-MMP-9 activator (pM9A). This unidentified activator specifically converted pro-MMP-9 but not pro-MMP-2, another member of the gelatinase family. The tissue-bound pM9A was steadily expressed and not regulated by TNF-α, which indicated that the cytokine-mediated activation of pro-MMP-9 might be regulated at the inhibitor level. Indeed, the skin constantly secreted tissue inhibitor of metalloproteinase-1 at the basal state. TNF-α, but not transforming growth factor-β, down-regulated this inhibitor. The TNF-α-mediated activation of pro-MMP-9 was tightly associated with down-regulation of tissue inhibitor of metalloproteinase-1 in a dose-dependent manner. To establish this linkage, we demonstrate that the recombinant tissue inhibitor of metalloproteinase-1 could block the activation of pro-MMP-9 by either the intact skin or skin fractions. Thus, these studies suggest a novel regulation for the proteolytic activation of MMP-9 in human tissue, which is mediated by tissue-bound activator and controlled by down-regulation of a specific inhibitor. The proteolytic activation of pro-matrix metalloproteinase (MMP)-9 by conversion of the 92-kDa precursor into an 82-kDa active form has been observed in chronic wounds, tumor metastasis, and many inflammation-associated diseases, yet the mechanistic pathway to control this process has not been identified. In this report, we show that the massive expression and activation of MMP-9 in skin tissue from patients with chronically unhealed wounds could be reconstituted in vitro with cultured normal human skin by stimulation with transforming growth factor-β and tumor necrosis factor (TNF)-α. We dissected the mechanistic pathway for TNF-α induced activation of pro-MMP-9 in human skin. We found that proteolytic activation of pro-MMP-9 was mediated by a tissue-associated chymotrypsin-like proteinase, designated here as pro-MMP-9 activator (pM9A). This unidentified activator specifically converted pro-MMP-9 but not pro-MMP-2, another member of the gelatinase family. The tissue-bound pM9A was steadily expressed and not regulated by TNF-α, which indicated that the cytokine-mediated activation of pro-MMP-9 might be regulated at the inhibitor level. Indeed, the skin constantly secreted tissue inhibitor of metalloproteinase-1 at the basal state. TNF-α, but not transforming growth factor-β, down-regulated this inhibitor. The TNF-α-mediated activation of pro-MMP-9 was tightly associated with down-regulation of tissue inhibitor of metalloproteinase-1 in a dose-dependent manner. To establish this linkage, we demonstrate that the recombinant tissue inhibitor of metalloproteinase-1 could block the activation of pro-MMP-9 by either the intact skin or skin fractions. Thus, these studies suggest a novel regulation for the proteolytic activation of MMP-9 in human tissue, which is mediated by tissue-bound activator and controlled by down-regulation of a specific inhibitor. matrix metalloproteinase basement membrane zone l-1-chloro-3-(4-tosylamido)-7-amino2-heptanone-HCl l-1-chloro-3-(4-tosylamido)-4-phenyl-2-butanone Dulbecco's modified Eagle's medium tumor necrosis factor transforming growth factor pro-MMP-9 activator tissue inhibitor of metalloproteinase bullous pemphigoid Matrix metalloproteinases (MMPs)1 are essential for remodeling of the extracellular matrix in physiologic and pathologic conditions (1Werb Z. Cell. 1997; 91: 439-442Abstract Full Text Full Text PDF PubMed Scopus (1132) Google Scholar, 2Parks W.C. Wound Repair Regen. 1999; 7: 423-432Crossref PubMed Scopus (333) Google Scholar). Within the MMP family, MMP-9 (gelatinase B; EC3.4.24.35) is particularly important, because it has a documented role in many human diseases. Like most MMPs, MMP-9 is secreted as a latent zymogen that is maintained by the interaction between a cysteine in the N-terminal pro-domain and the active-site zinc atom. Proteolytic cleavage of the pro-domain is a common control mechanism for MMP activation, which triggers a conformational change of the enzyme and is termed the “cysteine switch” (3Springman E.B. Angleton E.L. Birkedal-Hansen H. Van Wart H.E. Proc. Natl. Acad. Sci. U. S. A. 1990; 87: 364-368Crossref PubMed Scopus (620) Google Scholar). The conversion of pro-MMP-9 with an apparent molecular mass of 92-kDa to the 82-kDa active MMP-9 has been commonly observed in the pathogenesis of many diseases (4Birkedal-Hansen H. Moore W.G. Bodden M.K. Windsor L.J. Birkedal-Hansen B. DeCarlo A. Engler J.A. Crit. Rev. Oral Biol. Med. 1993; 4: 197-250Crossref PubMed Scopus (2639) Google Scholar). Metastasis is a multistep process, including detachment of cancer cells from a primary site, invasion into surrounding tissue through breakdown matrix, spreading through circulation, and proliferation in distant organs. Breakdown of the basement membrane zone (BMZ) is necessary to allow malignant cells to migrate from the primary location. MMP-9 is not normally expressed in developed tissues, yet it is highly expressed in many cancers (5Sier C.F. Kubben F.J. Ganesh S. Heerding M.M. Griffioen G. Hanemaaijer R. van Krieken J.H. Lamers C.B. Verspaget H.W. Br. J. Cancer. 1996; 74: 413-417Crossref PubMed Scopus (284) Google Scholar, 6Wood M. Fudge K. Mohler J.L. Frost A.R. Garcia F. Wang M. Stearns M.E. Clin. Exp. Metastasis. 1997; 15: 246-258Crossref PubMed Scopus (160) Google Scholar, 7Zucker S. Wieman J. Lysik R.M. Imhof B. Nagase H. Ramamurthy N. Liotta L.A. Golub L.M. Invasion Metastasis. 1989; 9: 167-181PubMed Google Scholar). During the early phase of breast cancer, only pro-MMP-9 is increased. As the cancer stage increases, evidenced by skin invasion or lymphovascular permeation, active MMP-9 is found (8Rha S.Y. Kim J.H. Roh J.K. Lee K.S. Min J.S. Kim B.S. Chung H.C. Breast Cancer Res. Treat. 1997; 43: 175-181Crossref PubMed Scopus (46) Google Scholar). Similarly, sequential expression and activation of pro-MMP-9 has been observed in liver metastasis (9Zeng Z.S. Guillem J.G. Br. J. Cancer. 1998; 78: 349-353Crossref PubMed Scopus (36) Google Scholar). An interesting pattern of MMP-9 expression has also been documented in wound healing. In the normal repair of acute trauma or burn wound, pro-MMP-9 is transiently expressed and declines with the progress of healing (10Tarlton J.F. Vickery C.J. Leaper D.J. Bailey A.J. Br. J. Dermatol. 1997; 137: 506-516Crossref PubMed Scopus (77) Google Scholar, 11Young P.K. Grinnell F. J. Invest. Dermatol. 1994; 103: 660-664Abstract Full Text PDF PubMed Scopus (85) Google Scholar). On the other hand, persistent expression of a larger amount of MMP-9, especially the active 82-kDa MMP-9, has been repeatedly documented in chronic wounds (12Wysocki A.B. Staiano-Coico L. Grinnell F. J. Invest. Dermatol. 1993; 101: 64-68Abstract Full Text PDF PubMed Google Scholar, 13Wysocki A.B. Kusakabe A.O. Chang S. Tuan T.L. Wound Repair Regen. 1999; 7: 154-165Crossref PubMed Scopus (97) Google Scholar, 14Yager D.R. Zhang L.Y. Liang H.X. Diegelmann R.F. Cohen I.K. J. Invest. Dermatol. 1996; 107: 743-748Abstract Full Text PDF PubMed Scopus (300) Google Scholar). Given the proteolytic function of MMP-9 in the digestion of BMZ components such as type IV collagen, the pathogenesis of these diseases could be due to the activity of MMP-9. A critical unanswered question regarding MMP-associated disease pathogenesis is the identification of specific factors controlling the expression and activation of the proteinase. MMP activities are regulated at multiple levels from their expression to activation by cleavage of the inhibitory domain as well as blockage by tissue inhibitors. Although the proteolytic activation of MMP-9 has been well documented in many diseases, the mechanism for the proteolytic conversion is not established. In this report, we show for the first time that the increased expression and activation of MMP-9 found in patients with chronic wounds could be reconstituted in cultured normal human skin by treatment with specific cytokines. Furthermore, we found that activation of pro-MMP-9 was mediated by a tissue-associated chymotrypsin-like proteinase. The TNF-α-mediated activation of pro-MMP-9 is controlled by down-regulation of the MMP inhibitor, TIMP-1. These findings provide a novel model to explain the MMP-9 activation in the pathogenesis of chronic wounds and tumor metastasis through the action of specific proinflammatory cytokines. Cytokines were purchased from R & D Systems (Minneapolis, MN). The antibodies against TIMP-1 (MAB13437) and the purified recombinant TIMP-1 protein (CC3328) were purchased from Chemicon International (Temecula, CA). The antibody for mast cell chymase (MS-1217) was from NeoMarkers (Fremont, CA). Aprotinin,l-1-chloro-3-(4-tosylamido)-7-amino-2-heptanone-HCl (TLCK), and l-1-chloro-3-(4-tosylamido)-4-phenyl-2-butanone (TPCK) were purchased from Roche Molecular Biochemicals. inhibitor was from The was purchased from was purchased from The was from was purchased human skin was as tissue from patients or of The skin was by in and at the skin was into of with in and in at with for To the of factors in the skin induced by the process, the medium was the the was in of with specific and was maintained at with and were from normal or human skin S. J.L. J. Invest. Dermatol. 1993; 101: Full Text PDF PubMed Google Scholar, T.L. M.E. J. Sci. 1994; 107: Google Scholar). The were in and with and The were with growth to the medium was with and for and basal medium for The human by at were in growth medium to The cells were by TNF-α in basal medium for in In this most of the gelatinase secreted in the medium is the 92-kDa The medium from was and by at The medium was to a by with in The gelatinase was by by against and at The of pro-MMP-9 was by with antibody against MMP-9 as Tuan T.L. H. J. Biol. Full Text Full Text PDF Scopus Google Scholar). were as in with To pro-MMP-2, the medium was by for the medium was by The gelatinase was purified by as In this most of the gelatinase is Tuan H. M. J. Sci. Google Scholar). The was by with antibody against were from at the of an unhealed burn wound, wound, and normal skin of The skin were by and in of with The were at with for The medium and tissue were at of TNF-α was as S. J.L. J. Invest. Dermatol. 1993; 101: Full Text PDF PubMed Google Scholar, J.F. Invest. PubMed Scopus Google Scholar). The skin tissue was and in by a The skin was by and at the tissue was by and The were to against and the were the of tissue were with of pro-MMP-9 with of The was at for by the of and of were to the The medium was with in the of and in was at with for in the was by with activities were developed in and at for at The activities were by with The medium or skin were by The protein was to The membrane was to antibodies against human TIMP-1 or mast cell chymase by with which were by expression and activation of MMP-9 been in the tissue of chronic wounds (12Wysocki A.B. Staiano-Coico L. Grinnell F. J. Invest. Dermatol. 1993; 101: 64-68Abstract Full Text PDF PubMed Google Scholar, 13Wysocki A.B. Kusakabe A.O. Chang S. Tuan T.L. Wound Repair Regen. 1999; 7: 154-165Crossref PubMed Scopus (97) Google Scholar, 14Yager D.R. Zhang L.Y. Liang H.X. Diegelmann R.F. Cohen I.K. J. Invest. Dermatol. 1996; 107: 743-748Abstract Full Text PDF PubMed Scopus (300) Google Scholar). To the factors that expression and activation of MMP-9, we the gelatinase and from the tissue of unhealed wounds, and we to the in vitro by cultured normal human skin. we show a gelatinase from a with a chronic from the unhealed wound, wound, and the surrounding normal skin were from a treatment for a The unhealed wound was a of that normally be to The were in with and at for This was to allow the of the factors by the The medium was by a As in gelatinase activities with apparent molecular of and the pro-MMP-9 and active MMP-9, were gelatinase activities were secreted from the normal skin and To the factors that the expression and activation of in human we a of that been found in chronic wounds and at tumor or of were to normal human skin in for and for the other for the were by As in this of only the expression of 92-kDa and only TNF-α the of 82-kDa MMP-9. The TNF-α-mediated of 82-kDa MMP-9 is by of the 92-kDa form by conversion to the 82-kDa form Tuan T.L. H. J. Biol. Full Text Full Text PDF Scopus Google Scholar). As of TNF-α with to expression and activation of MMP-9 either factor such as growth and not were or in The of and 82-kDa MMP-9 were by as in Tuan T.L. H. J. Biol. Full Text Full Text PDF Scopus Google Scholar). To this we the levels by of chronically unhealed wound, wound, and normal skin In a of and normal skin in the TNF-α was found to be in chronic wound tissue The of TNF-α found in chronic wound tissue is with the necessary to the proteolytic conversion of pro-MMP-9 in normal skin. we and TNF-α as factors for and activation of MMP-9, in chronic These that the and activation of MMP-9 observed in chronic wounds and are mediated through these cytokines. we that the TNF-α-mediated activation of pro-MMP-9 might be regulated through the of pM9A through an in of To this we the In the first we pM9A activity was by cytokines. human skin was with TNF-α and or for the medium and skin tissue were The skin were by and in The tissue was by for and the were to the To pM9A purified pro-MMP-9 was with the skin for by As in 92-kDa pro-MMP-9 was converted to the 82-kDa form by the tissue TNF-α not the pM9A We also pM9A activity was secreted into the We the pM9A activities in the medium as well as the medium that been of gelatinase in to the In the was MMP-9 that from the and the pro-MMP-9 was not converted Similarly, as in the pro-MMP-9 to be converted into the 82-kDa form in the Thus, either the tissue-bound pM9A is not secreted or is a specific inhibitor that is also secreted with the the in might to the expression of we a time human skin was into were in as were cultured in for and the skin were by pro-MMP-9 was to these tissue for pM9A The show that the tissue-associated pM9A activity is in the and increased the We protein in the skin was for the expression of human skin was cultured in with or TNF-α in the or of skin tissue was with and the were for pM9A activities by with purified The was by The show that treatment the pM9A activities in the skin TNF-α not the The pM9A activities from the skin were from the skin to the Thus, pM9A is in and is not regulated by We this unidentified by to inhibitors. The of human skin and purified pro-MMP-9 were with and inhibitor The show that but not other block the skin conversion of This that pM9A is a We the of pM9A through a of a specific inhibitor for and a specific inhibitor for chymotrypsin-like proteinase. The show that the tissue-associated pM9A activity is by at and by the inhibitor at which is the normal to block In has inhibitory at Thus, the tissue-associated pM9A an as yet unidentified chymotrypsin-like proteinase. was to pM9A from the skin tissue for this a was As was to the pM9A at Tuan T.L. H. J. Biol. Full Text Full Text PDF Scopus Google Scholar). We The skin was in by with either or The were and for pM9A activities by with purified As in pM9A at to In of the pM9A activity in the most pM9A activity in the fractions. In the pM9A could also be by and activity not We that the of of pM9A by either or was not due to or of pM9A but the of these to the from the skin cells in skin by of and including a chymotrypsin-like proteinase, pro-MMP-9 is a of cell from cells was to be to human pro-MMP-9 M. D.J. J. 1994; PubMed Scopus Google another that the mast cell chymase could the pro-MMP-9 by at the J.L. J. Biol. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar). To the human skin mast is we the of pM9A show that at could pM9A activity but to the mast cell chymase as by at to pM9A activity but could Thus, these of that the mast cell is not to be pM9A in human skin. in vitro has been as a activator for pro-MMP-9 Nagase H. J. Biol. Full Text PDF PubMed Google Scholar). in the with of the activation of MMP-9 was found to be which an pathway J. Van B. 1998; 91: PubMed Google Scholar). To this we TNF-α human skin and primary and were by TNF-α and for the medium was by for MMP-9 activation and for protein As the 92-kDa MMP-9 was induced by and the active 82-kDa was by TNF-α stimulation in human pro-MMP-9 was induced but activation was observed in either or A amount of was found expressed by human skin at basal and the protein was increased by TNF-α Similarly, protein was induced by TNF-α in and activation of pro-MMP-9 was In most of the is secreted as a pM9A is As in the specific inhibitor for to the activation of of these suggest that expression of is not to The of pM9A as an activator was by to another member of the gelatinase family. activation is to be mediated through the membrane type MMP with the of H. J. A. M. 1994; PubMed Scopus Google Scholar). We the tissue-associated pM9A could also The and from normal human skin were with purified and and the were by As pro-MMP-9 but not the is converted by the skin that active was from the and that amount was not increased by with the skin most of the pro-MMP-9 was converted to the 82-kDa pM9A is specific for pro-MMP-9 As in pM9A activity is steadily expressed in human and TNF-α has On the other hand, TNF-α the conversion of the activator was not regulated by TNF-α, we that the regulation might be at the inhibitor level. An from the of as in induced expression of pro-MMP-9 in normal skin but has conversion of the skin was of the pro-MMP-9 the factors were This that skin a pM9A inhibitor and that TNF-α, but not in the activation of we because it has been that TIMP-1 form a with pro-MMP-9 through their J. Biol. 1989; Full Text PDF PubMed Google Scholar, F. A.J. G. J. Biol. 1994; Full Text PDF PubMed Google Scholar). we TNF-α could TIMP-1. The medium from skin by TNF-α and was by with antibody against human TIMP-1. As TIMP-1 protein was steadily expressed at the basal and the protein was by or in with TNF-α the of TIMP-1 This of TNF-α-mediated down-regulation of TIMP-1 well with the cytokine-mediated conversion of pro-MMP-9 as in In the pro-MMP-9 activation inhibitor, TIMP-1 is as a secreted To this we the of of TNF-α the activation of pro-MMP-9 and TIMP-1 protein level. human skin was with a of of TNF-α for and the medium was for MMP-9 activation and TIMP-1 As in TNF-α a dose-dependent activation of pro-MMP-9 with action at The TIMP-1 protein was down-regulated by the cytokine-mediated activation of and down-regulation of TIMP-1 at To the of this we also for the inhibitor for and found that TNF-α has expression not Thus, the that TNF-α-mediated down-regulation of TIMP-1 in the conversion of To the role of TIMP-1 in the activation of we the purified recombinant TIMP-1 could the conversion of To the in which activation of pro-MMP-9 was we the TIMP-1 protein to the skin with purified pro-MMP-9 as As in the activation of pro-MMP-9 was by TIMP-1. most of the activation was were with human TIMP-1 with pro-MMP-9 as As the TIMP-1 the tissue-bound activation of pro-MMP-9 These that TIMP-1 pro-MMP-9 activation and that pro-MMP-9 activation is mediated by down-regulation of TIMP-1. In this we for the first time a novel model for the proteolytic activation of pro-MMP-9 in human skin. As in multiple including specific a inhibitor, and a tissue-bound in the regulation of pro-MMP-9 activation in human skin. In tissue, MMP-9 is and the inhibitor, is constantly During process, the expression of The MMP by a with which to the tissue-associated TNF-α is also it TIMP-1. pro-MMP-9 be converted by the tissue-associated chymotrypsin-like We that this model be to the pathogenesis of many inflammation-associated human diseases. these are in in diseases such as chronic wounds J. 1998; Full Text Full Text PDF PubMed Scopus Google Scholar, R. J. G. J.S. J. 1997; PubMed Scopus Google Scholar, H. Wound Repair Regen. PubMed Google and cancer Wang L.J. M. M. G. 1999; Google Scholar, R. A. M. A. Cancer Res. 1990; Google Scholar, G. M. A. Cancer. 1999; PubMed Scopus Google Scholar, van Breast Cancer Res. PubMed Scopus Google we that these be the factors for MMP-9 expression and activation in these conditions and to basement membrane MMP-9 has been in the pathogenesis of of diseases. A function for MMP-9 has been in the remodeling of the BMZ of the which is for type IV collagen, the in BMZ and type collagen, which the BMZ to the L.M. PubMed Scopus Google Scholar). The between wounds and MMP-9 is to be to a breakdown of the matrix which migrate to the The for a role for MMP-9 in BMZ remodeling from the of a skin disease bullous pemphigoid which is by the of the from the at the BMZ and is by and S. J. Invest. Dermatol. Full Text PDF PubMed Scopus Google Scholar). has been reconstituted in a model through of antibodies against a protein the basal to BMZ Z. L.A. J.L. D.J. J.A. J. Clin. Invest. 1993; PubMed Scopus Google Scholar). The of MMP-9 to has been by the in vitro cleavage of M. M. W.C. J. Clin. Invest. 1994; PubMed Scopus Google Scholar). for this model from the which are to induced bullous pemphigoid Z. L.A. Z. R.M. J. Exp. Med. 1998; PubMed Scopus Google Scholar). model components in the control of MMP-9 is the tissue-associated chymotrypsin-like proteinase, the unidentified We this specific is not yet the by and other for and L. pM9A is a chymotrypsin-like proteinase. The of pM9A interesting We found that such as pM9A from tissue, the components such as and to This that pM9A to a in which is to be an extracellular The of pM9A also a to this protein through the We that the of pM9A here provide the for the of this enzyme in the we provide that for the and mast cell are not to be We mast cell as a for pM9A because mast cells are associated with skin the basal this chymase is in and it is by The to this chymase as pM9A from the pM9A but not the and the chymase but not other mast cell chymase MMP-9 These studies M. D.J. J. 1994; PubMed Scopus Google Scholar, J.L. J. Biol. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar, J. Clin. Invest. 1996; PubMed Scopus Google Scholar). We that the be due to the of in the in this that the mast cell is not to be the in vitro was to pro-MMP-9 Nagase H. J. Biol. Full Text Full Text PDF PubMed Scopus Google Scholar). In this we the role of in pro-MMP-9 activation in human skin and provide a that expression of is not for MMP-9 In the inhibitor for not the pro-MMP-9 and pM9A are is and pM9A is Although we that we these as the the molecular identification of which be the of we that TNF-α-mediated activation of pro-MMP-9 by human skin was through of To the pM9A activities are steadily expressed and not regulated by the cytokines. This to a that TNF-α-mediated activation of pro-MMP-9 is at the inhibitor level. We that we this inhibitor as TIMP-1. The most of for a pM9A inhibitor from the of In the pro-MMP-9 but to the medium was from the tissue, the skin tissue could This that the skin an inhibitor, which in the tissue-associated pM9A from This pM9A inhibitor the it be expressed at basal and not down-regulated by it be down-regulated or by it be secreted as a down-regulation of the pM9A inhibitor be to the activation of and the of the inhibitor block the activation of We provide in this that TIMP-1 of these TIMP-1 is steadily expressed by most of TIMP-1 is secreted as a TNF-α and this down-regulation with activation of pro-MMP-9 in a dose-dependent and TIMP-1 is to skin it the activation of TIMP-1 is the only inhibitor regulated by TNF-α is to This be by of TIMP-1 from the medium and the pM9A inhibitor function is also An question we not yet is the of down-regulation of it could be at the of or at the such as protein The down-regulation of TIMP-1 is to through the or of the because we the secreted and tissue-associated and the amount of the inhibitor is The findings we here show that multiple including specific tissue-bound proteinase, and in the activation of pro-MMP-9 in human skin. This with the of multiple explain to MMP-9 activation the cell In we also to the proteolytic activation by the and Tuan T.L. H. J. Biol. Full Text Full Text PDF Scopus Google Scholar). This is in with the activation of pro-MMP-2, which has been to the membrane type H. J. A. M. 1994; PubMed Scopus Google Scholar). A of the primary between pro-MMP-9 and that are at their N-terminal the activation cleavage are This also that is a mechanism for the activation of these for in control and we that the model we here be to other human skin. This model also provide for in many inflammation-associated diseases. the between and tumor metastasis by the and activation of MMP-9 BMZ tumor cell liver induced by or other has been reconstituted by of TNF-α into B. K. S. J. Med. 7: PubMed Scopus Google Scholar). In these MMP-9 was induced and in the the liver could be by either or of MMP inhibitor. Thus, factors such as TIMP-1 and the as we show in this also in the liver identification of the factors in MMP-9 expression and activation in human tissue provide for treatment of the diseases that matrix We the of levels in tissue by of We A. of for and of this We for the human skin.
33
A matrix metalloproteinase expressed on the surface of invasive tumour cells
Hiroshi Sato, Takahisa Takino, Yasunori Okada et al. · Nature · 1994 · 2.6K citations
S M Wilhelm, Ivan E. Collier, Barry L. Marmer et al. · Journal of Biological Chemistry · 1989 · 1.1K citations · Full text
Eric B. Springman, Eddie L. Angleton, Henning Birkedal‐Hansen et al. · Proceedings of the National Academy of Sciences · 1990 · 712 citations